Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.

ABSTRACT:

Background

There is uncertainty whether low-risk episodes of febrile neutropaenia (FN) in adult cancer patients are best managed in the in- or outpatient setting.

Methods

A Monte Carlo cost-utility model was created to compare four treatment strategies for low-risk FN: (1) treatment in hospital with intravenous antibiotics (HospIV); (2) early discharge after 48 h in-patient observation, followed by oral outpatient treatment (EarlyDC); (3) outpatient management with IV antibiotics (HomeIV); and (4) outpatient management with oral antibiotics (HomePO). The model used a health-care payer perspective and a time horizon of one FN episode. Outcome measures were quality-adjusted FN episodes (QAFNE), costs (Canadian dollars) and incremental cost-effectiveness ratios (ICER). Paramete

SUBMITTER: Teuffel O 

PROVIDER: S-EPMC3101923 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature